MDGL
Madrigal Pharmaceuticals, Inc.
512.39
1 x 510.39
1 x 512.33
bid
ask
-
6.35
1.22%
1 @ 04:00 PM
511.23 -1.16 (0.23%)
| Ytd | -12.01% | |
| 1y | 60.16% |
500.97
day range
522.18
267.56
52 week range
602.83
| Open | 518.00 | Prev Close | 518.74 | Low | 500.97 | High | 522.18 | Mkt Cap | 11.75B |
| Vol | 200.29K | Avg Vol | 360.56K | EPS | -12.86 | P/E | N/A | Forward P/E | 40.55 |
| Beta | -1.01 | Short Ratio | 10.69 | Inst. Own | 104.78% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-06 | 50-d Avg | 477.19 | 200-d Avg | 463.24 | 1yr Est | 672.79 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-05-06 | 2026-03 | 0 | N/A | N/A | N/A |
| 2026-02-19 | 2025-12 | 0.04 | N/A | -2.61 | -6.00% |
| 2025-11-04 | 2025-09 | 0 | N/A | -3.1 | -156.57% |
| 2025-08-05 | 2025-06 | 0 | N/A | 1.58 | 45.40% |
| 2025-05-01 | 2025-03 | 0 | N/A | 0.3 | 8.29% |
| 2025-02-26 | 2024-12 | 0 | N/A | 1.41 | 34.22% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-02-20 | B of A Securities | Upgrade | Neutral | Neutral |
| 2026-01-28 | Barclays | Upgrade | Overweight | |
| 2026-01-20 | Citizens | Upgrade | Market Outperform | Market Outperform |
| 2025-12-19 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2025-12-11 | B. Riley Securities | Upgrade | Buy | Buy |
| 2025-11-21 | HC Wainwright & Co. | Upgrade | Buy | Buy |
Profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2025-08-19 | BAKER BROS ADVISORS, L.P. | Unknown | 0.00 | Purchase |
| 2025-03-12 | CRAVES FREDERICK B | Director | 383.55K | Sale |
| 2026-03-05 | DIER MARDI C | Chief Financial Officer | 12.49K | Sale |
| 2026-01-08 | FRIEDMAN PAUL A | Director | 842.70K | Sale |
| 2026-03-05 | HUNTSMAN CAROLE A | Officer | 12.69K | Sale |
| 2026-03-05 | KELLEY SHANNON T | General Counsel | 12.14K | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | Baker Bros. Advisors, LP | 2.14M | 1.10B | 9.34% |
| 2025-12-30 | RTW Investments LP | 1.99M | 1.02B | 8.69% |
| 2025-12-30 | Vanguard Group Inc | 1.81M | 926.86M | 7.89% |
| 2025-12-30 | Avoro Capital Advisors LLC | 1.81M | 926.14M | 7.88% |
| 2025-12-30 | PAULSON & CO. INC. | 1.71M | 874.92M | 7.44% |
| 2025-12-30 | Blackrock Inc. | 1.64M | 842.75M | 7.17% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 574.39K | 294.31M | 2.50% |
| 2026-02-27 | iShares Trust-iShares Russell 2000 ETF | 452.26K | 231.74M | 1.97% |
| 2025-12-30 | JANUS INVESTMENT FUND-Janus Henderson Forty Fund | 429.42K | 220.03M | 1.87% |
| 2025-12-30 | VANGUARD INDEX FUNDS-Vanguard Small-Cap Index Fund | 412.29K | 211.26M | 1.80% |
| 2026-01-30 | VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund | 398.13K | 204.00M | 1.74% |
| 2026-03-30 | SPDR SERIES TRUST-State Street SPDR S&P Biotech ETF | 205.48K | 105.29M | 0.90% |
Split
| Split | Date |
|---|---|
| 1 : 35 | 2016-07-25 |
